Elsevier

Drug Resistance Updates

Volume 8, Issues 1–2, February–April 2005, Pages 85-97
Drug Resistance Updates

Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy

https://doi.org/10.1016/j.drup.2005.04.003Get rights and content

Abstract

In addition to their well-known anti-malarial activity, artemisinin and its derivatives (1,2,4-trioxanes) possess potent activity against tumor cells in the nano- to micromolar range. Candidate genes that may contribute to the sensitivity and resistance of tumor cells to artemisinins were identified by pharmacogenomic and molecular pharmacological approaches. Target validation was performed using cell lines transfected with candidate genes or corresponding knockout cells. These genes are from classes with different biological function; for example, regulation of proliferation (BUB3, cyclins, CDC25A), angiogenesis (vascular endothelial growth factor and its receptor, matrix metalloproteinase-9, angiostatin, thrombospondin-1) or apoptosis (BCL-2, BAX). Artesunate triggers apoptosis both by p53-dependent and -independent pathways. Anti-oxidant stress genes (thioredoxin, catalase, γ-glutamyl-cysteine synthetase, glutathione S-transferases) as well as the epidermal growth factor receptor confer resistance to artesunate. Cell lines over-expressing genes that confer resistance to established anti-tumor drugs (MDR1, MRP1, BCRP, dihydrofolate reductase, ribonucleotide reductase) were not cross-resistant to artesunate, indicating that this drug has a different target and is not subject to multidrug resistance. The Plasmodium translationally controlled tumor protein (TCTP) represents a known target protein of artemisinin and its derivatives in the malaria parasite. The microarray-based mRNA expression of human TCTP correlated with sensitivity to artesunate in tumor cells, suggesting that human TCTP contributes to response of tumor cells to the drug. The multi-factorial nature of cellular response to artemisinin and its derivatives may be beneficial to treat otherwise drug-resistant tumors and may explain why resistance development has not been observed in either cancer or malaria.

Introduction

Cancer chemotherapy is limited by the development of drug resistance in tumors and adverse side effects in patients. The search for novel anti-tumor agents that circumvent these limitations has turned to natural sources, in particular plants used in traditional folk medicines. This approach has already proven successful. Camptothecin from Camptotheca acuminata and paclitaxel from Taxus brevifolia are outstanding examples of natural products as chemotherapeutic agents (Wall and Wani, 1995).

The genus Artemisia L. belongs to the family of Compositae. More than 350 Artemisia species are known, many of which have been used in traditional folk medicines for various applications (cough, blood circulation, diuresis, hypertension, allergy, parasites, etc.). Sesquiterpene lactones, flavonoids, coumarins, acetylenes, and sterols have been isolated from Artemisia species, some of which reveal anti-malarial, anti-viral, anti-tumor, anti-pyretic, anti-coagulant, anti-spasmodic, and other effects (Tan et al., 1998).

Artemisinin, a sesquiterpene lactone from Artemisia annua L. (qinghao, Sweet wormwood) has raised considerable attention in past years. The plant has been used in China for more than two millenia. Its first description dates back to the third century bc. Ge Hong (281–340 ad) recommended tea-brewed leaves to treat fever and chills in his “Handbook of Prescriptions for Emergency Treatment”. The “Compendium of Materia Medica” published by Li Shizen in 1596 cited Ge Hong's prescription. The fact that qinghao tea has withstood the centuries may be taken as a clue for the usefulness and activity of this prescription of traditional Chinese medicine (TCM).

A program for the discovery of new anti-malarial drugs from TCM launched by the Chinese government led in 1972 to the identification of artemisinin (qinghaosu), the active principle of A. annua L. (Klayman, 1985, Butler and Wu, 1992). Today, several tons per year of artemisinin are extracted from A. annua L. plants for pharmaceutical utilization in Asian countries (Haynes, 2001), which points to a preservation issue of wild-growing plants and which necessitates the cultivation in plantations for large scale production. Due to the low solubility of artemisinin in oil and water, several semi-synthetic derivatives have been developed, including artemether, arteether, artesunate, and others (Fig. 1). The attractiveness of the artemisinin class of anti-malarials is due to their activity against multidrug-resistant Plasmodium falciparum and Plasmodium vivax strains (Price et al., 1998). Another salient feature is the lack of severe side effects in malaria patients (Ribeiro and Olliaro, 1998), although neurotoxicity occurs in animals after prolonged treatment with supra-therapeutic doses (Brewer et al., 1994, Kamchonwongpaisan et al., 1997, Gordi and Lepist, 2004).

Section snippets

Anti-proliferative activity

During the past years, a number of tumor cell lines have been tested for their sensitivity to artemisinin and first generation derivatives (artesunate, artemether, arteether). While artemisinin and its derivatives kill malaria parasites at nanomolar concentrations, they exhibit cytotoxicity towards mammalian cells in the nanomolar to micromolar range (Sun et al., 1992, Woerdenbag et al., 1993, Zheng, 1994; Lai and Singh, 1995; Efferth et al., 1996, Beekman et al., 1997a).

Using a panel of 55

Multidrug resistance

A salient feature of artemisinin and its derivatives is the lack of cross-resistance with other anti-malarials. Drug resistance is a huge problem in malaria treatment worldwide. Artemisinin and its derivatives are valuable for the treatment of otherwise unresponsive, multidrug-resistant malaria parasites (Price et al., 1998). Although Plasmodium strains resistant to artemisinin and its derivatives have been selected in vitro (Walker et al., 2000), resistance to this drug class has not been

Pharmacogenomics

Because the molecular mechanisms of action of artemisinin and its derivatives in tumor cells are largely unknown, we applied pharmacogenomic approaches to explore the molecular determinants of sensitivity and resistance to this drug class. We mined the genome-wide mRNA expression database and correlated the expression data with the IC50 values for artesunate as reported by us (Efferth et al., 2001) and other artemisinin derivatives deposited in the database. This is a hypothesis-generating

Oxidative stress and iron

In malaria parasites, artemisinin acts by a two-step mechanism. It is first activated by intraparasitic heme-iron, which catalyzes the cleavage of the endoperoxide. The Plasmodium trophozoites and schizonts live within red blood cells. Hemoglobin serves as an amino acid source, being taken up by the parasites into food vacuoles where enzymatic degradation takes place (Semenov et al., 1998, Shenai et al., 2000). The release of heme-iron during hemoglobin digestion facilitates the cleavage of the

Toxicity

Neurotoxicity has been reported in safety studies with movement disturbances and neuropathic changes occur in the hindbrain of intramuscularly treated dogs, rats, and monkeys after using extremely high doses or after prolonged exposure (Kamchonwongpaisan et al., 1997). Such effects have not been seen in malaria patients. A recent clinical safety review of 108 clinical studies enrolling 9241 patients provided ample evidence that artemisinins are safe and without serious adverse events or severe

Apoptosis

Since most anti-cancer drugs kill tumor cells by the induction of apoptosis, it is reasonable to assume that the same is true for artemisinin and its derivatives. There are two main pathways that trigger apoptosis (Schimmer et al., 2001, Fulda and Debatin, 2003, Green and Kroemer, 2004). Both the extrinsic and the intrinsic pathway of apoptosis are regulated by the tumor suppressor gene p53 (Haupt et al., 2003). Members of the tumor necrosis factor family activate the receptor-mediated

Angiogenesis

In the angiogenic process, the formation of new blood vessels from pre-existing ones is essential for the supply of tumors with oxygen and nutrients and for the spread of metastatic cells throughout the body (Folkman, 1992). Angiogenesis is promoted by numerous factors including cytokines, VEGF, bFGF, PDGF, etc. and negatively regulated by angiostatin, endostatin, thrombospondin, TIMP, and others. These factors, which are produced in tumor cells as well as in surrounding stromal cells, act in a

Perspectives

Considerable progress has been made during the past years towards understanding the molecular modes of action of artemisinin and its derivatives against tumor cells. Diverse lines of research show that the cellular response to artemisinin and its derivatives is multi-factorial in nature (Fig. 5). This may be beneficial in treating otherwise drug-resistant tumors and may explain why the development of artemisinin resistance has not yet been encountered in cancer cell lines or malaria patients.

References (128)

  • T. Efferth et al.

    Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron

    Free Radic. Biol. Med.

    (2004)
  • T. Efferth et al.

    Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines

    Biochem. Pharmacol.

    (2004)
  • J. Fishwick et al.

    The toxicity of artemisinin and related compounds on neuronal and glial cells in culture

    Chem. Biol. Interact.

    (1995)
  • S. Fulda et al.

    Apoptosis pathways: turned on their heads?

    Drug Resist. Update

    (2003)
  • T. Gordi et al.

    Artemisinin derivatives: toxic for laboratory animals, safe for humans?

    Toxicol. Lett.

    (2004)
  • C. Huan-Huan et al.

    Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell

    Cancer Lett.

    (2004)
  • A.I. Ivanov et al.

    Cisplatin binding sites on human albumin

    J. Biol. Chem.

    (1998)
  • S.H. Kim et al.

    Differential involvement of protein kinase C in human promyelocytic leukemia cell differentiation enhanced by artemisinin

    Eur. J. Pharmacol.

    (2003)
  • S. Krishna et al.

    Arteminisins: mechanisms of action and potential for resistance

    Drug Resist. Update

    (2004)
  • H. Lai et al.

    Effects of artemisinin-tagged holotransferrin on cancer cells

    Life Sci.

    (2005)
  • C.H. Lee et al.

    NMR studies on novel antitumor drug candidates, deoxoartemisinin and carboxypropyldeoxoartemisinin

    Biochem. Biophys. Res. Commun.

    (2000)
  • Y. Li et al.

    Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle

    Bioorg. Med. Chem. Lett.

    (2001)
  • Y. Li et al.

    Synthesis and cytotoxicity of dihydroartemisinin ethers containing cyanoarylmethyl group

    Bioorg. Med. Chem.

    (2003)
  • M.F. McCarty

    Turning an ‘Achilles’ Heel’ into an asset-activation of HIF-1alpha during angiostatic therapy will increase tumor sensitivity to iron-catalyzed oxidative damage

    Med. Hypotheses

    (2003)
  • J.C. Moore et al.

    Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat

    Cancer Lett.

    (1995)
  • S. Oh et al.

    Synthesis and antiangiogenic activity of thioacetal artemisinin derivatives

    Bioorg. Med. Chem.

    (2004)
  • S. Parapini et al.

    Evidence that haem iron in the malaria parasite is not needed for the antimalarial effects of artemisinin

    FEBS Lett.

    (2004)
  • A.G. Payne

    Exploiting intracellular iron and iron-rich compounds to effect tumor cell lysis

    Med. Hypotheses

    (2003)
  • T. Peleg-Shulman et al.

    Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt–protein adducts of cisplatin and transplatin towards biological nucleophiles

    J. Inorg. Biochem.

    (2002)
  • G.H. Posner et al.

    New chemical and biological aspects of artemisinin-derived trioxane dimers

    Bioorg. Med. Chem.

    (2002)
  • R. Ravi et al.

    NF-κB in cancer – a friend turned foe

    Drug Resist. Update

    (2004)
  • D. Sadava et al.

    Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells

    Cancer Lett.

    (2002)
  • A.D. Schimmer et al.

    Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view

    Blood

    (2001)
  • S. Shankar et al.

    Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications

    Drug Resist. Update

    (2004)
  • B.R. Shenai et al.

    Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum

    J. Biol. Chem.

    (2000)
  • W. Asawamahasakda et al.

    Reaction of antimalarial endoperoxides with specific parasite proteins

    Antimicrob. Agents Chemother.

    (1994)
  • A.S. Baldwin

    Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB

    J. Clin. Invest.

    (2001)
  • J. Baselga

    Why the epidermal growth factor receptor? The rationale for cancer therapy

    Oncologist

    (2002)
  • A.C. Beekman et al.

    Stability of artemisinin in aqueous environments: impact on its cytotoxic action to Ehrlich ascites tumour cells

    J. Pharm. Pharmacol.

    (1997)
  • A.C. Beekman et al.

    Stereochemistry-dependent cytotoxicity of some artemisinin derivatives

    J. Nat. Prod.

    (1997)
  • A.C. Beekman et al.

    Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells

    Planta Med.

    (1998)
  • Berger, T.G., Dieckmann, D., Efferth, T., Schultz, E.S., Funk, J.-O., Baur, A., Schuler, G. Artesunate in the treatment...
  • A.K. Bhattacharjee et al.

    Stereoelectronic properties of antimalarial artemisinin analogues in relation to neurotoxicity

    Chem. Res. Toxicol.

    (1999)
  • J. Bhisutthibhan et al.

    Immunoprecipitation of H-3 dihydroartemisinin translationally controlled tumor protein (Tctp) adducts from Plasmodium falciparum-infected erythrocytes by using anti-Tctp antibodies

    Antimicrob. Agents Chemother.

    (2001)
  • T.G. Brewer et al.

    Fatal neurotoxicity of arteether and artmether

    Am. J. Trop. Med. Hyg.

    (1994)
  • A.R. Butler et al.

    Artemisinin (qinghaosu) – a new type of antimalarial drug

    Chem. Soc. Rev.

    (1992)
  • A.R. Butler et al.

    EPR evidence for the involvement of free radicals in the iron-mediated decomposition of qinghaosu (artemisinin) and some derivatives: antimalarial action of some polycyclic endoperoxides

    Free Radic. Res.

    (1998)
  • P.J. Carder et al.

    Glutathione S-transferase in human brain

    Neuropathol. Appl. Neurobiol.

    (1990)
  • H.H. Chen et al.

    Antimalarial dihydroartemisinin also inhibits angiogenesis

    Cancer Chemother. Pharmacol.

    (2004)
  • H.H. Chen et al.

    Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1

    Pharmacology

    (2004)
  • Cited by (154)

    View all citing articles on Scopus
    View full text